Rituxan

Cancer Treatment

Rituxan is used to treat specific types of cancer that affect the white blood cells. These include:

• Non-Hodgkin's Lymphoma (NHL): It is used for various forms of NHL, including follicular lymphoma and diffuse large B-cell lymphoma. It may be used alone or with other chemotherapy medications.
• Chronic Lymphocytic Leukemia (CLL): It is used in combination with other drugs to treat this type of blood and bone marrow cancer.

Autoimmune Disorders

Rituxan is also prescribed for several conditions where the immune system is overactive or attacks healthy tissue:

• Rheumatoid Arthritis: It is used to reduce the signs and symptoms of moderate to severe rheumatoid arthritis in adults. It is typically prescribed when other treatments have not worked well enough.
• Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA): These are rare disorders that cause inflammation of the blood vessels.
• Pemphigus Vulgaris: This is a rare autoimmune disease that causes severe blistering of the skin and the lining of the mouth, nose, throat, and genitals.

Targeting B-cells

Rituxan belongs to a class of medications known as monoclonal antibodies. These are laboratory-made proteins designed to recognize and bind to specific targets in the body. Rituxan specifically targets a protein called CD20, which is found on the surface of B-lymphocytes (B-cells), a type of white blood cell.

How it destroys cells

When Rituxan attaches to the CD20 protein on a B-cell, it works in several ways to eliminate the cell:

• Immune system activation: It signals your own immune system to attack and kill the targeted B-cells.
• Direct cell death: The binding process itself can sometimes trigger the cell to self-destruct.
• Complement-mediated lysis: It can activate other proteins in the blood that help destroy the B-cell membrane.

Treating different conditions

In certain types of cancer, such as non-Hodgkin lymphoma or chronic lymphocytic leukemia, B-cells grow and multiply too quickly. By destroying these cells, Rituxan helps slow or stop the progression of the disease.

In autoimmune conditions like rheumatoid arthritis, B-cells are involved in the process that causes the immune system to attack healthy joints and tissues. By reducing the number of B-cells, Rituxan helps decrease inflammation and protect the body from further damage.

Common Side Effects

The most common side effects of Rituxan often occur during or within 24 hours of the infusion. These symptoms are usually mild to moderate and may include:

• Fever and chills
• Headache
• Nausea and diarrhea
• Fatigue or unusual weakness
• Muscle or joint pain
• Runny or stuffy nose
• Itching or mild rash

Serious Side Effects

Rituxan can cause serious and potentially life-threatening side effects. Seek medical help immediately if you notice any of the following:

• Infusion Reactions: Symptoms such as hives, swelling of the face or throat, chest pain, or difficulty breathing.
• Severe Infections: Signs of infection including fever, persistent cough, or pain during urination. Rituxan can increase the risk of serious bacterial, fungal, or viral infections.
• Progressive Multifocal Leukoencephalopathy (PML): A rare brain infection that may cause confusion, dizziness, loss of balance, vision changes, or difficulty talking.
• Hepatitis B Reactivation: In people who have had Hepatitis B, the virus can become active again, causing yellowing of the skin or eyes and dark urine.
• Severe Skin and Mouth Reactions: Painful sores, ulcers, or blisters on the skin, lips, or inside the mouth.
• Organ Problems: Chest pain or irregular heartbeat (heart issues) and changes in urination or swelling in the legs (kidney issues).

Boxed Warnings

Rituxan has several boxed warnings for serious and potentially life-threatening conditions:

• Infusion-Related Reactions: Severe and fatal reactions can occur, typically during the first infusion. Symptoms may include hives, swelling, difficulty breathing, and chest pain.
• Severe Skin and Mouth Reactions: Conditions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.
• Hepatitis B Virus (HBV) Reactivation: The virus can become active again in people who have had it in the past, potentially leading to liver failure or death. Screening for HBV is required before starting treatment.
• Progressive Multifocal Leukoencephalopathy (PML): This is a rare, serious brain infection caused by the JC virus. It can lead to severe disability or death.

Other Serious Precautions

Infections

Treatment may increase the risk of serious infections, including bacterial, fungal, and viral infections. Healthcare providers typically monitor for signs of infection during and after treatment.

Tumor Lysis Syndrome (TLS)

In patients treated for certain cancers, the rapid breakdown of cancer cells can cause kidney failure and electrolyte imbalances. This usually occurs within 12 to 24 hours after the first dose.

Heart and Kidney Problems

Rituxan may cause heart rhythm disturbances or chest pain, especially in those with a history of heart disease. It can also lead to kidney damage or failure.

Gastrointestinal Issues

Serious stomach and bowel problems, including blockages or holes in the bowel wall (perforation), have occurred in some patients.

Vaccinations

Live vaccines should not be administered shortly before or during treatment with Rituxan, as the medication affects the immune system's response.

Pregnancy

Rituxan can cross the placenta and may affect the development of the fetus. Specifically, it may lead to a decrease in B-cells, a type of white blood cell, in the newborn. Because of these risks, healthcare providers usually advise the following:

• Use effective birth control during treatment and for at least 12 months after the last dose.
• Inform your doctor immediately if you become pregnant or plan to become pregnant while using this medication.

Breastfeeding

It is not known whether Rituxan passes into human breast milk. Due to the potential for serious adverse reactions in a nursing infant, it is generally recommended to avoid breastfeeding during treatment and for at least 6 months following the final dose. Discuss the risks and benefits of breastfeeding with your healthcare provider to determine the safest approach for you and your baby.

Available Forms

Rituxan is supplied in the following form:

• Intravenous Injection: A sterile, preservative-free liquid solution intended for dilution and administration as an infusion into a vein.

This medication is not available in oral forms such as tablets or capsules. It must be administered by a healthcare provider in a clinical setting, such as a hospital or infusion center, where patients can be monitored for potential reactions during the procedure.

FDA Approval and Indications

Rituxan was first approved by the U.S. Food and Drug Administration (FDA) in 1997. It is currently approved for the treatment of several conditions in adults and, in some instances, children:

• Non-Hodgkin's Lymphoma (NHL)
• Chronic Lymphocytic Leukemia (CLL)
• Rheumatoid Arthritis (RA), in combination with methotrexate
• Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
• Moderate to severe Pemphigus Vulgaris (PV)

Boxed Warnings

The FDA requires a boxed warning for Rituxan due to the risk of severe and potentially life-threatening side effects. These include:

• Infusion-Related Reactions: Severe reactions can occur during or shortly after the infusion.
• Severe Mucocutaneous Reactions: Serious skin and mouth reactions, including Stevens-Johnson Syndrome and toxic epidermal necrolysis, have been reported.
• Hepatitis B Virus (HBV) Reactivation: The virus can become active again in patients who previously had the infection, potentially leading to liver failure or death.
• Progressive Multifocal Leukoencephalopathy (PML): A rare and often fatal brain infection caused by the JC virus.

Regulatory Safety Communications

The FDA has issued multiple safety communications regarding Rituxan. Healthcare providers are required to screen all patients for Hepatitis B infection before starting treatment. Additionally, patients must be monitored closely for signs of neurological changes that could indicate PML or severe skin reactions that require immediate discontinuation of the drug.

Factors Affecting Cost

The total price of Rituxan treatment is influenced by several variables. Because it is a biologic medication administered by a healthcare professional, costs often include both the drug itself and the clinical fees for the infusion process. Key factors include:

• Dosage and Frequency: The amount of medication needed and how often it is administered depends on the specific condition being treated.
• Treatment Setting: Costs may vary depending on whether the infusion is received in a hospital, a specialized infusion center, or a doctor's office.
• Insurance Coverage: Most insurance plans, including Medicare, provide coverage for Rituxan when used for FDA-approved indications. However, patients may still be responsible for deductibles, copayments, or coinsurance.

Biosimilar Alternatives

Rituxan has several FDA-approved biosimilars. A biosimilar is a biologic medication that is highly similar to the original brand-name drug. Biosimilars are often available at a lower cost than the reference product, which may help reduce the financial burden of treatment.

Financial Assistance Programs

The manufacturer of Rituxan may offer financial assistance programs, such as copay cards for patients with commercial insurance or patient assistance programs for those who are uninsured or underinsured. Some independent charitable foundations also provide grants to help cover the costs of biologic therapies for specific diseases.